Result of AGM

RNS Number : 1857H

Arix Bioscience Plc

05 June 2017

 

Results of Annual General Meeting

LONDON, 5 June, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, announces that its Annual General Meeting (the "Meeting") was held on Monday 5 June 2017 at 2pm (London time). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 26 April 2017 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 14 and 19 were passed as ordinary resolutions. Resolutions 15 to 18 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.  

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
1	To receive the Directors' report and the accounts for the Company for the period ended 31 December 2016	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
2	To approved the Directors' Remuneration Policy	41,408,348	88.59	5,333,387	11.41	46,741,735	48.64%	942
3	To re-elect Dr Joseph Anderson as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
4	To re-elect Sir John Banham as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
5.	To re-elect Professor Sir Chris Evans as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
6	To re-elect Dr Franz Humer as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
7	To re-elect Lord John Hutton of Furness as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
8	To re-elect Professor Trevor Jones as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
9	To re-elect Jonathan Peacock as a Director	46,251,849	98.95	490,200	1.05	46,742,049	48.64%	628
10.	To Re-elect James Rawlingson as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
11.	To re-elect David U'Prichard as a Director	46,742,049	100.00	0	0.00	46,742,049	48.64%	628
12	To re-appoint PwC LLP as auditors of the Company	46,741,735	100.00	0	0.00	46,741,735	48.64%	942
13	To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors	46,741,735	100.00	0	0.00	46,741,735	48.64%	942
14	To authorise the Directors to allot shares	46,742,049	100.00	628	0.00	46,742,677	48.64%	0
15	To authorise the Directors to disapply statutory pre-emption rights in respect of 5% of the Company's issued share capital	44,140,479	94.43	2,601,570	5.57	46,742,049	48.64%	628
16	To authorise the Directors to disapply statutory pre-emption rights in respect of an additional 5% of the Company's issued share capital	43,277,458	92.59	3,464,591	7.41	46,742,049	48.64%	628
17	To authorise the Company to buy back shares	46,740,165	99.99	2,512	0.01	46,742,677	48.64%	0
18	To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice	46,742,677	100.00	0	0.00	46,742,677	48.64%	0
19	To authorise the Company to purchase its own Deferred Shares	46,741,735	100.00	942	0.00	46,742,677	48.64%	0

Notes:

1.    Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.

2.    A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

3.    The number of shares in issue at 6:00 p.m. on 1 June 2017 was 96,091,083 (the "Share Capital"). The Company does not hold any shares in treasury.

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism which can be accessed at www.hemscott.com/nsm.do

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

[phone]

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

 

END

 

 

RAGOKPDQQBKDBAK